TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Show more
Location: 200 Minuteman Road, Suite 302, Andover, MA, 01810, United States | Website: https://www.transmedics.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
3.805B
52 Wk Range
$55.00 - $177.37
Previous Close
$124.78
Open
$122.70
Volume
2,556,635
Day Range
$109.59 - $123.50
Enterprise Value
4.742B
Cash
310.1M
Avg Qtr Burn
N/A
Insider Ownership
3.03%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Organ Care System (OCS™) Details Medical Device for Liver Transplant | Approved Quarterly sales | |
Organ Care System (OCS™) Details Medical Device for Heart Transplant | Approved Quarterly sales |